FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure - Global Kidney Academy

ReachMD Healthcare Image

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Optimizing AAV Outcomes: Maintenance Therapies
Optimizing AAV Outcomes: Maintenance Therapies
MinuteCE®
Optimizing AAV Outcomes: Maintenance Therapies
0.75 program credits
- Bernhard Hellmich, MD
- Silke R. Brix, MD, MRCP, SCPR
0.75 program credits
Implementing the SOC Induction Therapies in AAV 
Implementing the SOC Induction Therapies in AAV 
MinuteCE®
Implementing the SOC Induction Therapies in AAV 
0.75 program credits
- Silke R. Brix, MD, MRCP, SCPR
- Bernhard Hellmich, MD
0.75 program credits
Managing Patients With AAV in the Rheumatology Clinic
Managing Patients With AAV in the Rheumatology Clinic
MinuteCE®
Managing Patients With AAV in the Rheumatology Clinic
0.75 program credits
- Andreas Kronbichler, MD
- Bernhard Hellmich, MD
0.75 program credits
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
CME/CE
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
0.25 credits
- Mikhail Kosiborod, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.25 credits